- Home
- KEP vs EXEL Comparison
KEP vs EXEL Comparison
Compare KEP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEP
- EXEL
- Stock Information
- Founded
- KEP 1961
- EXEL 1994
- Country
- KEP South Korea
- EXEL United States
- Employees
- KEP N/A
- EXEL N/A
- Industry
- KEP Electric Utilities: Central
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KEP Utilities
- EXEL Health Care
- Exchange
- KEP Nasdaq
- EXEL Nasdaq
- Market Cap
- KEP 9.4B
- EXEL 9.7B
- IPO Year
- KEP N/A
- EXEL 2000
- Fundamental
- Price
- KEP $8.18
- EXEL $34.45
- Analyst Decision
- KEP
- EXEL Buy
- Analyst Count
- KEP 0
- EXEL 18
- Target Price
- KEP N/A
- EXEL $31.72
- AVG Volume (30 Days)
- KEP 87.7K
- EXEL 2.6M
- Earning Date
- KEP 12-01-2024
- EXEL 10-29-2024
- Dividend Yield
- KEP N/A
- EXEL N/A
- EPS Growth
- KEP N/A
- EXEL 441.02
- EPS
- KEP 4.40
- EXEL 1.55
- Revenue
- KEP $70,353,869,926.00
- EXEL $2,081,598,000.00
- Revenue This Year
- KEP $5.44
- EXEL $20.53
- Revenue Next Year
- KEP $3.10
- EXEL $1.54
- P/E Ratio
- KEP $3.68
- EXEL $22.26
- Revenue Growth
- KEP 8.48
- EXEL 17.31
- 52 Week Low
- KEP $6.69
- EXEL $19.20
- 52 Week High
- KEP $9.55
- EXEL $36.60
- Technical
- Relative Strength Index (RSI)
- KEP 54.90
- EXEL 67.10
- Support Level
- KEP $7.58
- EXEL $27.86
- Resistance Level
- KEP $8.30
- EXEL $36.49
- Average True Range (ATR)
- KEP 0.10
- EXEL 0.98
- MACD
- KEP -0.02
- EXEL -0.01
- Stochastic Oscillator
- KEP 74.07
- EXEL 74.10
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.